ELMSFORD, N.Y., Sept. 9, 2015 /PRNewswire/ -- BioScrip, Inc.
(NASDAQ: BIOS) ("BioScrip" or the "Company") today announced that
R. Carter Pate, a member of
BioScrip's Board of Directors since May
2015, has become an NACD Board Leadership Fellow, the
highest level of credentialing for corporate directors and
corporate governance professionals offered by The National
Association of Corporate Directors. He joins more than 50 other
corporate directors from leading corporations around the world who
also earned the prestigious credential during the second quarter of
2015.
"It is an honor to join the distinguished and diverse group of
individuals who make up NACD's Fellowship program," said Pate.
"We share a commitment to advancing the highest standards of
boardroom leadership, and the insights I've gained through NACD's
Fellowship program will be key to my professional growth as a
director and the contributions I make to BioScrip."
"As the emphasis on corporate governance intensifies, having one
of our board members recognized with such respected credentials
demonstrates how seriously we take fiduciary responsibility," said
Myron Z. Holubiak, Chairman of the
Board of Directors of BioScrip. "It is yet another indication of
the strength of the Board of Directors we have assembled to oversee
and support the implementation of the Company's operations and
financial improvement plan. Moreover, it is imperative that
we operate with the highest integrity and transparency as we
continue to execute our strategy to streamline the Company so as to
effect meaningful change and drive shareholder value."
An NACD Fellowship, considered the definitive director
credential, is a comprehensive program of study developed to
educate directors about perennial and emerging boardroom issues and
best practices. Completion of this rigorous program demonstrates a
director's serious commitment to exemplary corporate
governance.
Candidates complete a strong foundation course which focuses on
topical matters and committee-specific issues, followed by
additional NACD education within a 12-month period. NACD Fellows
renew their status every year, maintaining and advancing their
knowledge with continuous learning and peer-led
collaboration.
R. Carter Pate, CPA, has been a
director of the Company since May
2015. Mr. Pate serves as Chair of the Company's Audit
Committee and its newly-formed Financial Improvement Implementation
Committee, and he is a member of the Company's Management
Development and Compensation Committee.
Mr. Pate previously served as Chief Executive Officer of MV
Transportation, Inc., the largest privately-owned passenger
transportation contracting firm based in the U.S. ("MV") from 2011
to 2014 and continues to serve as an independent strategic advisor
to MV. From 1996 to 2011, Mr. Pate was employed by
PricewaterhouseCoopers, LLP ("PwC"), where he held increasingly
responsible positions including the U.S. and Global Managing
Partner of PwC's Capital Projects and Infrastructure practice, the
Global and U.S. Managing Partner of PwC's Health Care Practice, and
as a Partner and Leader in PwC's U.S. Restructuring Practices.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and
home healthcare management solutions. BioScrip partners with
healthcare providers, including physicians, hospital systems,
skilled nursing facilities, and with healthcare payors to provide
patients better access to high quality, efficient post-acute care
services. BioScrip operates with a commitment to bring infusion
therapy services into the home or alternate-site settings. By
collaborating with the full spectrum of healthcare professionals
and the patient, BioScrip provides cost-effective care that is
driven by clinical excellence, customer service, and values that
promote positive outcomes and an enhanced quality of life for those
it serves.
Forward-Looking Statements – Safe Harbor
This press release includes statements that may constitute
"forward-looking statements," including projections of certain
measures of the Company's results of operations, projections of
future levels of certain charges and expenses, and other statements
regarding the Company's financial improvement plan and strategy.
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. You can
identify these statements by the fact that they do not relate
strictly to historical or current facts. In some cases,
forward-looking statements can be identified by words such as
"may," "should," "could," "anticipate," "estimate," "expect,"
"project," "outlook," "aim," "intend," "plan," "believe,"
"predict," "potential," "continue" or comparable terms. Because
such statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such forward-looking statements. Investors are cautioned
that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and that
actual results may differ materially from those in the
forward-looking statements as a result of various factors.
Important factors that could cause or contribute to such
differences include but are not limited to risks associated with:
the Company's ability implement its financial improvement plan to
reduce operating costs and focus its business on its Infusion
Services segment; reductions in federal, state and commercial
reimbursement for the Company's products and services; increased
government regulation related to the health care and insurance
industries; as well as the risks described in the Company's
periodic filings with the Securities and Exchange Commission. The
Company does not undertake any duty to update these forward-looking
statements after the date hereof, even though the Company's
situation may change in the future. All of the forward-looking
statements herein are qualified by these cautionary statements.
Logo -
http://photos.prnewswire.com/prnh/20130117/NY44138LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bioscrip-board-of-director-r-carter-pate-becomes-nacd-board-leadership-fellow-300139242.html
SOURCE BioScrip, Inc.